Information Provided By:
Fly News Breaks for January 21, 2020
Jan 21, 2020 | 07:25 EDT
H.C. Wainwright analyst Yi Chen raised Veru's price target to $6 from $4.50 after VERU-944 reduced the frequency of hot flashes in a Phase 2 study. The data demonstrate that 50mg zuclomiphene could effectively reduce the frequency of ADT-induced hot flashes, which has no FDA-approved therapy, Chen tells investors in a research note. The analyst reiterates a Buy rating on the shares.
News For VERU From the Last 2 Days
There are no results for your query VERU